{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Organ+Cancers&page=2",
    "query": {
      "condition": "Solid Organ Cancers",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Organ+Cancers&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T07:49:51.125Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01058239",
      "title": "Bortezomib Plus Rituximab for EBV+ PTLD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Post-transplant Lymphoproliferative Disease",
        "Solid Organ Transplant",
        "Stem Cell Transplant (Bone Marrow Transplant)",
        "Epstein Barr Virus Infections"
      ],
      "interventions": [
        {
          "name": "bortezomib",
          "type": "DRUG"
        },
        {
          "name": "rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2011-11",
      "completion_date": "2017-11",
      "has_results": true,
      "last_update_posted_date": "2018-02-15",
      "last_synced_at": "2026-05-22T07:49:51.125Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01058239"
    },
    {
      "nct_id": "NCT03093909",
      "title": "Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Neoplasm of Bone and Articular Cartilage",
        "Malignant Neoplasms of Female Genital Organs",
        "Malignant Neoplasms of Independent (Primary) Multiple Sites",
        "Malignant Neoplasms of Lip Oral Cavity and Pharynx",
        "Malignant Neoplasm of Male Genital Organs",
        "Malignant Neoplasms of Mesothelial and Soft Tissue",
        "Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma",
        "Malignant Neoplasms of Thyroid and Other Endocrine Glands",
        "Malignant Neoplasms of Urinary Tract",
        "Melanoma and Other Malignant Neoplasms of Skin"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "12 Years to 50 Years"
      },
      "enrollment_count": 44,
      "start_date": "2017-11-22",
      "completion_date": "2027-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-20",
      "last_synced_at": "2026-05-22T07:49:51.125Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03093909"
    },
    {
      "nct_id": "NCT03435952",
      "title": "Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Neoplasm of Breast",
        "Malignant Neoplasms of Digestive Organs",
        "Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System",
        "Malignant Neoplasms of Female Genital Organs",
        "Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites",
        "Malignant Neoplasms of Independent (Primary) Multiple Sites",
        "Malignant Neoplasms of Lip Oral Cavity and Pharynx",
        "Malignant Neoplasms of Male Genital Organs",
        "Malignant Neoplasms of Mesothelial and Soft Tissue",
        "Malignant Neoplasms of Respiratory and Intrathoracic Organs",
        "Malignant Neoplasms of Thyroid and Other Endocrine Glands",
        "Malignant Neoplasms of Urinary Tract"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Clostridium Novyi-NT",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Doxycycline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2018-07-10",
      "completion_date": "2026-10-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-16",
      "last_synced_at": "2026-05-22T07:49:51.125Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03435952"
    },
    {
      "nct_id": "NCT00054483",
      "title": "Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Grade III Lymphomatoid Granulomatosis",
        "Adult Nasal Type Extranodal NK/T-cell Lymphoma",
        "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue",
        "Nodal Marginal Zone B-cell Lymphoma",
        "Recurrent Adult Burkitt Lymphoma",
        "Recurrent Adult Diffuse Large Cell Lymphoma",
        "Recurrent Adult Diffuse Mixed Cell Lymphoma",
        "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma",
        "Recurrent Adult Grade III Lymphomatoid Granulomatosis",
        "Recurrent Adult Immunoblastic Large Cell Lymphoma",
        "Recurrent Adult Lymphoblastic Lymphoma",
        "Recurrent Grade 1 Follicular Lymphoma",
        "Recurrent Grade 2 Follicular Lymphoma",
        "Recurrent Grade 3 Follicular Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Recurrent Small Lymphocytic Lymphoma",
        "Refractory Multiple Myeloma",
        "Splenic Marginal Zone Lymphoma",
        "Stage III Multiple Myeloma",
        "Stage IV Adult Burkitt Lymphoma",
        "Stage IV Adult Diffuse Large Cell Lymphoma",
        "Stage IV Adult Diffuse Mixed Cell Lymphoma",
        "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma",
        "Stage IV Adult Immunoblastic Large Cell Lymphoma",
        "Stage IV Adult Lymphoblastic Lymphoma",
        "Stage IV Grade 1 Follicular Lymphoma",
        "Stage IV Grade 2 Follicular Lymphoma",
        "Stage IV Grade 3 Follicular Lymphoma",
        "Stage IV Mantle Cell Lymphoma",
        "Stage IV Marginal Zone Lymphoma",
        "Stage IV Small Lymphocytic Lymphoma",
        "Unspecified Adult Solid Tumor, Protocol Specific",
        "Waldenström Macroglobulinemia"
      ],
      "interventions": [
        {
          "name": "bortezomib",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 69,
      "start_date": "2003-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-05-16",
      "last_synced_at": "2026-05-22T07:49:51.125Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00054483"
    },
    {
      "nct_id": "NCT00024310",
      "title": "Paclitaxel, Folic Acid, and Lometrexol in Treating Patients With Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Drug/Agent Toxicity by Tissue/Organ",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "folic acid",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "lometrexol",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "DRUG"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2001-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-09-17",
      "last_synced_at": "2026-05-22T07:49:51.125Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00024310"
    },
    {
      "nct_id": "NCT04554914",
      "title": "A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epstein-Barr Virus (EBV)-Associated Diseases",
        "EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD)",
        "EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD)",
        "EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD)",
        "EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD)",
        "Solid Organ Transplant Complications",
        "Lymphoproliferative Disorders",
        "Allogeneic Hematopoietic Cell Transplant",
        "Stem Cell Transplant Complications",
        "EBV+ Sarcomas",
        "Leiomyosarcoma"
      ],
      "interventions": [
        {
          "name": "Tabelecleucel",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pierre Fabre Medicament",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 190,
      "start_date": "2021-07-14",
      "completion_date": "2028-05",
      "has_results": false,
      "last_update_posted_date": "2026-04-27",
      "last_synced_at": "2026-05-22T07:49:51.125Z",
      "location_count": 23,
      "location_summary": "Los Angeles, California • Orange, California • Palo Alto, California + 18 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04554914"
    },
    {
      "nct_id": "NCT07426484",
      "title": "Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cutaneous Squamous Cell Carcinoma",
        "Skin Cancer"
      ],
      "interventions": [
        {
          "name": "Cosibelimab",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2026-07",
      "completion_date": "2032-12-15",
      "has_results": false,
      "last_update_posted_date": "2026-02-23",
      "last_synced_at": "2026-05-22T07:49:51.125Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07426484"
    },
    {
      "nct_id": "NCT03685539",
      "title": "DECT in Imaging Patients With Solid Organ Cancer With Intracranial Metastasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Malignant Neoplasm",
        "Metastatic Malignant Neoplasm in the Brain"
      ],
      "interventions": [
        {
          "name": "Dual-Energy Computed Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2018-08-24",
      "completion_date": "2023-08-29",
      "has_results": false,
      "last_update_posted_date": "2023-08-31",
      "last_synced_at": "2026-05-22T07:49:51.125Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03685539"
    },
    {
      "nct_id": "NCT03110159",
      "title": "DUSA: Cyclic PDT for the Prevention of AK & NMSC in Solid Organ Transplant Recipients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Skin Cancer",
        "Non-melanoma Skin Cancer",
        "Sun Damaged Skin",
        "Actinic Keratosis"
      ],
      "interventions": [
        {
          "name": "Levulan® Kerastick®",
          "type": "DRUG"
        },
        {
          "name": "BLU-U Blue Light Photodynamic Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medical Dermatology Specialists",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2017-08-29",
      "completion_date": "2024-02-20",
      "has_results": false,
      "last_update_posted_date": "2024-03-15",
      "last_synced_at": "2026-05-22T07:49:51.125Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03110159"
    },
    {
      "nct_id": "NCT00003611",
      "title": "Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Non-melanomatous Skin Cancer"
      ],
      "interventions": [
        {
          "name": "acitretin",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 129,
      "start_date": "2000-05",
      "completion_date": "2003-06",
      "has_results": false,
      "last_update_posted_date": "2016-07-13",
      "last_synced_at": "2026-05-22T07:49:51.125Z",
      "location_count": 11,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 8 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Urbana",
          "state": "Illinois"
        },
        {
          "city": "Des Moines",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003611"
    }
  ]
}